Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
Public ClinicalTrials.gov record NCT04855136. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)
Study identification
- NCT ID
- NCT04855136
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Celgene
- Industry
- Enrollment
- 21 participants
Conditions and interventions
Conditions
Interventions
- BB2121 Biological
- CC-220 Drug
- BMS-986405 Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2021
- Primary completion
- Apr 24, 2025
- Completion
- Apr 24, 2025
- Last update posted
- Jul 8, 2026
2021 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 117 | Birmingham | Alabama | 10016 | — |
| Local Institution - 113 | San Francisco | California | 94143 | — |
| Local Institution - 101 | Jacksonville | Florida | 32224-1865 | — |
| Local Institution - 104 | Atlanta | Georgia | 30322 | — |
| Local Institution - 120 | Atlanta | Georgia | 30342 | — |
| Local Institution - 114 | Chicago | Illinois | 60611 | — |
| Local Institution - 108 | Boston | Massachusetts | 02117 | — |
| Local Institution - 124 | Boston | Massachusetts | 02215 | — |
| Local Institution - 109 | Hackensack | New Jersey | 07601 | — |
| New York University Langone | New York | New York | 10016 | — |
| Local Institution - 110 | New York | New York | 10032 | — |
| Local Institution - 111 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 118 | Philadelphia | Pennsylvania | 19107 | — |
| Local Institution - 103 | Nashville | Tennessee | 37203 | — |
| Local Institution - 107 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04855136, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 8, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04855136 live on ClinicalTrials.gov.